1. Clinical & Scientific Overview
Tacrolimus Ointment, Calcipotriol & Coal Tar / Salicylic Acid (TIP-MED-000460, Reference Code [12.28]) is classified under
Emergency & Critical-Care Medicines as a Topical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Keratolytics (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).
Representative Indian Formulations (for identification only): Tacrolimus Ointment: Tacroz / Tacroz Forte (Glenmark — 0.03%, 0.1%), Topgraf (Glaxo); Pimecrolimus 1% Cream: Elidel, Pacroma. | Strengths: Tacrolimus Ointment: **0.03% w/w** (Children 2–15 yr & sensitive adult facial skin) and **0.1% w/w** (Adults >=16 yr) (10 g, 20 g tube). Pimecrolimus Cream: **1.0% w/w**. Calcipotriol Ointment/Scalp Solution: **0.005% w/w (50 mcg/g)**.
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Topical Calcineurin Inhibitor (Steroid-Sparing Immunomodulator), Vitamin D3 Analogue & Keratolytics (Schedule H)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Tacrolimus Ointment (0.
4. Therapeutic Indications & Evidence-Supported Uses
- Tacrolimus Ointment (0
- 03%/0
- 1%) & Pimecrolimus 1% Cream: **Steroid-Sparing Second-Line & Proactive Maintenance Therapy for Atopic Dermatitis (Eczema), Facial/Eyelid/Flexural Dermatitis, Vitiligo (repigmentation!), and Oral/Genital Lichen Planus** (**CRITICAL ADVANTAGE**: Topical Calcineurin Inhibitors inhibit T-cell I
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Tacrolimus Ointment / Pimecrolimus Cream: Apply a thin layer to affected skin **TWICE DAILY** until clearance, then switch to **Proactive Twice-Weekly Maintenance (e.g., Saturday & Sunday nights)** on previously affected eczema hotspots to prevent flares! (In Vitiligo: Apply BD for 3–6 months). (Duration: Active flare (2–6 weeks) followed by intermittent twice-weekly eczema maintenance or chronic vitiligo/psoriasis therapy)
Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: Independent of food; apply Tacrolimus to dry skin (wait 1–2 hours after bathing/moisturising if burning occurs); | Best Time of Day: Morning & Evening (BD) or Bedtime (Daivobet OD)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD
Renal: Avoid Calcipotriol and large-area Salicylic Acid in severe CKD
7. Contraindications, Precautions & High-Risk Warnings
- TACROLIMUS & CALCIPOTRIOL WARNINGS: (1) Do not apply Tacrolimus/Pimecrolimus to active viral/bacterial skin infections (Herpes simplex [eczema herpeticum], warts, impetigo), Netherton syndrome, or children 3–6%) over large body areas in children or CKD causes systemic Salicylism** (tinnitus, hyperventilation, metabolic acidosis)!
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Tacrolimus: **Transient local burning, warmth, stinging, or pruritus** at the application site during the first **3–5 days** of use (occurs in 30–50% due to initial substance-P release from cutaneous sensory nerves — **completely subsides after Day 4–5 as nerv
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL INCOMPATIBILITY — SALICYLIC ACID INACTIVATES CALCIPOTRIOL!: **Salicylic Acid is acidic and chemically destroys/inactivates Calcipotriol on contact** — NEVER apply Salicylic Acid ointment/lotion at the same time as Calcipotriol (Daivonex)! (If descaling is needed, apply Salicylic Acid at a c
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- FOUR VITAL COUNTER RULES: (1) **Tacroz (Tacrolimus) and Elidel are NOT steroids** — they are completely safe to use on delicate skin like the **eyelids, face, neck, and skin folds** without thinning the skin or causing stretch marks
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Tacrolimus Ointment: **0.03% w/w** (Children 2–15 yr & sensitive adult facial skin) and **0.1% w/w** (Adults >=16 yr) (10 g, 20 g tube). Pimecrolimus Cream: **1.0% w/w**. Calcipotriol Ointment/Scalp Solution: **0.005% w/w (50 mcg/g)**.). Missed-Dose Rule: Apply when remembered
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)